Comparing two erythropoietin medicines for kidney disease
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial tests two similar medicines that help your body make red blood cells. It is for people with advanced chronic kidney disease who are on dialysis, and aims to see if the study medicine works as well as the standard one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 5 chronic kidney disease (kidney failure).
- You are on hemodialysis (a machine cleans your blood).
- You have not had a condition called pure red cell aplasia (when your body stops making red blood cells).
- You do not have antibodies against erythropoietin (a protein that makes red blood cells).
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study is testing a new way to manage anemia (low red blood cells) in people on long-term dialysis. It aims to improve how doctors treat this common issue.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This study tests a new erythropoietin (a medicine that helps your body make red blood cells) and compares it to an approved version called Eprex. It is for healthy adults to see how the two medicines work in the body and if they are safe.
This study looks at how well erythropoietin (a drug that helps your body make red blood cells) works for people with end-stage kidney disease who are on regular hemodialysis. It also checks if metabolic syndrome (a group of conditions like high blood sugar, high blood pressure, and extra belly fat) affects how well this drug works.
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
Hear when a new Anemia of Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.